Treating peri-implantitis-induced, medication-related jaw osteonecrosis
Investigators evaluated the outcomes of treatment among patients with peri-implantitis-induced medication-related osteonecrosis of the jaw.
In a systematic review published in Oral Diseases, the investigators used the PubMed/MEDLINE, Cochrane CENTRAL, Web of Science and Scopus databases to identify 24 studies reporting on the clinical and radiographic features as well as treatment outcomes of 111 patients with peri-implantitis-induced medication-related osteonecrosis of the jaw.
The adverse effects of the condition included pain, bone exposure and suppuration — with the lesions predominantly presenting with stage II or III disease. In a majority of the cases, one or two implants were involved; however, in nearly 20 of the cases, three or more implants were involved. The investigators found that 61 of the cases were treated with implant removal and debridement of the necrotic bone, and 85% of the patients achieved complete wound healing.
The findings suggested that antiresorptive treatment may be a risk factor for peri-implantitis-induced medication-related osteonecrosis of the jaw in patients with dental implants.
Read more: Oral Diseases
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.